Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II

Detalles Bibliográficos
Autores principales: Lei, Chuqi, Kong, Xiangyi, Sullivan, Ryan J., Wu, Caisheng, Wang, Dawei, Zhang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940897/
https://www.ncbi.nlm.nih.gov/pubmed/36814493
http://dx.doi.org/10.3389/fphar.2023.1136373
_version_ 1784891168393265152
author Lei, Chuqi
Kong, Xiangyi
Sullivan, Ryan J.
Wu, Caisheng
Wang, Dawei
Zhang, Lin
author_facet Lei, Chuqi
Kong, Xiangyi
Sullivan, Ryan J.
Wu, Caisheng
Wang, Dawei
Zhang, Lin
author_sort Lei, Chuqi
collection PubMed
description
format Online
Article
Text
id pubmed-9940897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99408972023-02-21 Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II Lei, Chuqi Kong, Xiangyi Sullivan, Ryan J. Wu, Caisheng Wang, Dawei Zhang, Lin Front Pharmacol Pharmacology Frontiers Media S.A. 2023-02-06 /pmc/articles/PMC9940897/ /pubmed/36814493 http://dx.doi.org/10.3389/fphar.2023.1136373 Text en Copyright © 2023 Lei, Kong, Sullivan, Wu, Wang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lei, Chuqi
Kong, Xiangyi
Sullivan, Ryan J.
Wu, Caisheng
Wang, Dawei
Zhang, Lin
Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title_full Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title_fullStr Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title_full_unstemmed Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title_short Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
title_sort editorial: toxicity mechanism and clinical features of pd-1/pd-l1 inhibitors in treatment of cancer, volume ii
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940897/
https://www.ncbi.nlm.nih.gov/pubmed/36814493
http://dx.doi.org/10.3389/fphar.2023.1136373
work_keys_str_mv AT leichuqi editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii
AT kongxiangyi editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii
AT sullivanryanj editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii
AT wucaisheng editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii
AT wangdawei editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii
AT zhanglin editorialtoxicitymechanismandclinicalfeaturesofpd1pdl1inhibitorsintreatmentofcancervolumeii

Ejemplares similares